Phase 3 Readout
NVO: Phase 3 Topline: Long-term Safety and Efficacy of Semaglutide s.c. Once-weekly on Weight Management in Children and A
December 7, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 7, 2026
- Company
- Novo Nordisk A/S (NVO)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: Long-term Safety and Efficacy of Semaglutide s.c. Once-weekly on Weight Management in Children and A
- Company
- Novo Nordisk A/S (NVO)
- Indication
- Obesity